Porton Advanced introduces MaxCyte ExPERT GTx Flow Electroporation instrument for cell therapy

Porton Advanced, a subsidiary of China headquartered contract development and manufacturing organisation (CDMO) Porton Pharma Solutions, has introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system.

This equipment, known for its exceptional high transfection efficiency and cell viability, is capable of handling flexible transfection volumes and covering the entire process from research to clinical stages and cGMP production. It also seamlessly scales up for large-volume preparations. MaxCyte has already successfully supported the market launch of the world's first CRISPR/CAS9 gene-edited therapeutic, Casgevy.

By introducing the MaxCyte technology platform, Porton Advanced has further strengthened its capabilities in non-viral electroporation for process development and clinical production. Currently, Porton Advanced has used MaxCyte to provide process development and production services at varying stages and clinical trials for multiple cell therapy projects.

For the process development and clinical production involved in electroporation technologies of different cell therapies, Porton Advanced will collaborate with MaxCyte's powerful technical and compliance teams by utilising the MaxCyte ExPERT GTx and other existing types of electroporation equipment to empower and accelerate the translation of gene and cell therapy drugs to clinics and ultimately, the market.